宫颈癌近距离治疗不可行时立体定向消融放疗推量
回顾性分析25例无法接受近距离治疗的宫颈癌患者,盆腔放疗后行SABR推量,中位剂量25 Gy/5次。3年局部控制率80.9%,总生存率77.1%,5例发生3级毒性,无4-5级毒性。SABR推量有效且可耐受,可作为近距离治疗不可行时的选择。
要点
- 盆腔放疗后SABR推量中位25 Gy/5次,3年局部控制率80.9%。
- 5例发生3级毒性(泌尿3例、胃肠3例),无4-5级毒性。
- 直肠累积D2cc EQD2对便血有边缘预测价值(P=0.051),阈值81.2 Gy。
核心结论
- 宫颈癌SABR推量有效且可耐受,虽不能替代近距离治疗,但近距离治疗不可行时可作为治疗选择。
研究设计与样本
- 单中心回顾性研究,纳入25例不适合近距离治疗的宫颈癌患者。
- 盆腔放疗25或28次,中位剂量45 Gy(范围44-50.4 Gy),后行SABR推量中位25 Gy(范围20-33 Gy),中位5次(范围4-6次)。
- 21例随访超过1年的患者纳入毒性分析,评估放疗3个月后发生的血尿和便血。
主要发现
- 放疗后中位随访2.85年(范围0.33-6.60年)。
- 3年局部控制率80.9%,局部区域控制率75.8%,无病生存率40.9%,总生存率77.1%。
- 5例发生3级毒性(泌尿3例、胃肠3例),无4-5级毒性报告。
- 单因素分析显示直肠累积D2cc EQD2对任何级别便血有边缘预测意义(P=0.051)。
- 膀胱累积D2cc EQD2对血尿无预测作用;ROC曲线分析直肠累积D2cc EQD2最佳阈值为81.2 Gy。
关键数值与推荐
- 直肠累积D2cc EQD2对任何级别便血的预测P=0.051。
- ROC曲线分析中直肠累积D2cc EQD2的最佳阈值为81.2 Gy。
临床怎么用
- 对于近距离治疗不可行的宫颈癌患者,可考虑盆腔放疗后SABR推量。
- 关注直肠累积D2cc EQD2,阈值81.2 Gy可能有助于预测便血风险。
局限性
- 单中心回顾性研究,样本量较小(25例),随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to analyze the treatment efficacy and safety of stereotactic ablative body radiotherapy (SABR) boost for cervical cancer patients not amenable to brachytherapy. METHODS: A retrospective review of the medical records from single institution of 25 eligible patients was performed. The patients underwent pelvic radiotherapy (RT) in 25 or 28 fractions with a median dose of 45 Gy (range 44-50.4 Gy). SABR boost was delivered after pelvic RT, with a median dose of 25 Gy (range 20-33 Gy), and a median fraction number of 5 (range 4-6). 21 patients with a follow-up period of more than one year were included in the toxicity analysis, and hematuria and hematochezia that occurred later than 3 months after the RT were graded. RESULTS: The median follow-up period after radiotherapy was 2.85 years (range 0.33-6.60). The 3-year local control, locoregional control, disease-free survival, and overall survival rates were 80.9%, 75.8%, 40.9%, and 77.1%, respectively. 5 patients experienced grade 3 toxicity (3 genitourinary, 3 gastrointestinal), and no grade 4-5 toxicity was reported. Univariate analysis showed that cumulative D2cc in equivalent dose in 2 Gy fractions (EQD2) of rectum was marginally predictive for any grade of hematochezia (P = 0.051). Cumulative D2cc EQD2 of bladder was not predictive for hematuria. In the receiver operating characteristic (ROC) curve analysis, the optimal threshold of cumulative rectal D2cc EQD2 was 81.2 Gy for any grade of hematochezia. CONCLUSION: SABR boost for cervical cancer was effective and tolerable. Although it cannot substitute brachytherapy, it can be a treatment option when brachytherapy is not possible.
引用
- Lee TH, Song C, Kim IA, et al. Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible. Radiat Oncol. 2021. PMID: 34384450. doi:10.1186/s13014-021-01877-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。